Pasithea Therapeutics (KTTA) Leases (2021 - 2024)
Pasithea Therapeutics (KTTA) has disclosed Leases for 4 consecutive years, with $32026.0 as the latest value for Q1 2024.
- Quarterly Leases fell 99.98% to $32026.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $32026.0 through Mar 2024, down 99.98% year-over-year, with the annual reading at $79271.0 for FY2023, 84.16% down from the prior year.
- Leases hit $32026.0 in Q1 2024 for Pasithea Therapeutics, down from $79271.0 in the prior quarter.
- In the past five years, Leases ranged from a high of $184.2 million in Q1 2023 to a low of $32026.0 in Q1 2024.
- Historically, Leases has averaged $23.2 million across 4 years, with a median of $419885.0 in 2023.
- Biggest five-year swings in Leases: increased 2.31% in 2023 and later plummeted 99.98% in 2024.
- Year by year, Leases stood at $21.5 million in 2021, then tumbled by 97.67% to $500428.0 in 2022, then tumbled by 84.16% to $79271.0 in 2023, then crashed by 59.6% to $32026.0 in 2024.
- Business Quant data shows Leases for KTTA at $32026.0 in Q1 2024, $79271.0 in Q4 2023, and $378453.0 in Q3 2023.